Is Aspen betting on the right HIV prevention product?

Posted in: Healthcare system, HIV, Latest

Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.

Is Aspen betting on the right HIV prevention product?

In The Spotlight | What are broadly neutralising antibodies and what do they mean for the fight against HIV?

Posted in: #InTheSpotlight, Access to Medicines, Healthcare system, HIV, Latest, Special Investigations, Spotlight

HIV is known for its ability to outsmart our immune system’s normal defences. A small number of people living with HIV are however able to generate more effective immune responses to HIV. In this special briefing, Catherine Tomlinson zooms in on broadly neutralising antibodies, the secret sauce in these immune responses.